Related Experiment Video
Updated: May 25, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Listeria monocytogenes and its products as agents for cancer immunotherapy
Patrick Guirnalda1, Laurence Wood, Yvonne Paterson
1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract:
This review covers the use of Listeria monocytogenes and its virulence factors as cancer immunotherapeutics. We describe their development as vectors to carry protein tumor antigen and eukaryotic DNA plasmids to antigen-presenting cells and efforts to harness their tumor-homing properties. We also describe their use as vectors of angiogenic molecules to induce an immune response that will destroy tumor vasculature. The background knowledge necessary to understand the biology behind the rationale to develop Listeria as a vaccine vector for tumor immunotherapy is included as well as a brief summary of the major therapies that have used this approach thus far.
Insights
Listeria monocytogenes are being developed as cancer immunotherapeutics. These bacteria are engineered as vectors to deliver tumor antigens and angiogenic molecules, stimulating an immune response against tumors.
Area of Science:
- Immunology
- Oncology
- Microbiology
Background:
- Listeria monocytogenes possesses unique properties making it a candidate for cancer immunotherapy.
- Understanding its virulence factors is key to developing effective cancer vaccines.
Purpose of the Study:
- To review the application of Listeria monocytogenes and its virulence factors in cancer immunotherapy.
- To explore the use of Listeria as a vaccine vector for tumor immunotherapy.
Main Methods:
- Engineering Listeria monocytogenes as a vector for delivering tumor antigens and DNA plasmids.
- Utilizing Listeria's tumor-homing capabilities for targeted delivery.
- Employing Listeria to deliver angiogenic molecules to disrupt tumor vasculature.
Main Results:
- Listeria monocytogenes can be engineered to target antigen-presenting cells.
- Harnessing tumor-homing properties enhances targeted cancer therapy.
- Listeria-mediated delivery of angiogenic molecules can induce anti-tumor immune responses.
Conclusions:
- Listeria monocytogenes shows promise as a versatile platform for cancer immunotherapy.
- Further development of Listeria-based vaccines could lead to novel cancer treatments.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

